Response to Mindfulness-Based Cognitive Therapy Differs Between Chronic and Episodic Migraine.
Elizabeth K. Seng, Alexandra B Conway, Amy S. Grinberg, Zarine S Patel, Maya Marzouk, Lauren Rosenberg, Christopher Metts, Melissa A Day, Mia T. Minen, Dawn C Buse, Richard B Lipton
Neurology. Clinical practice June 2021 DOI: 10.1212/cpj.0000000000000984 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Planned secondary analysis of a randomized clinical trial Peer reviewed |
|---|---|
| Sample size | 60 |
| Population | Adults with episodic migraine (6-14 headache days/month) or chronic migraine (15-30 headache days/month) |
| Intervention | Mindfulness-Based Cognitive Therapy for Migraine (MBCT-M) |
| Duration | 8 weekly individual sessions; assessments at months 0, 1, 2, and 4 |
| Measures | Headache Disability Inventory, Severe Migraine Disability Assessment Scale |
| Topics | Meditation |
| Registration | NCT02443519 |
| Key findings | Migraine type moderated MBCT-M's effect on headache disability: MBCT-M reduced the proportion reporting severe disability more in episodic migraine (-40.0% vs -14.3% with control) than in chronic migraine (-16.4% vs +8.7% with control). Headache Disability Inventory scores improved significantly with MBCT-M in episodic migraine (p = 0.011) but not chronic migraine (p = 0.268). The authors conclude MBCT-M is promising for reducing headache-related disability, with greater benefits in episodic than chronic migraine. |
Abstract
Evaluate whether the benefits of Mindfulness-Based Cognitive Therapy for Migraine (MBCT-M) on headache disability differs among people with episodic and chronic migraine (CM). This is a planned secondary analysis of a randomized clinical trial. After a 30-day baseline, participants were stratified by episodic (6-14 d/mo) and CM (15-30 d/mo) and randomized to 8 weekly individual sessions of MBCT-M or wait list/treatment as usual (WL/TAU). Primary outcomes (Headache Disability Inventory; Severe Migraine Disability Assessment Scale [scores ≥ 21]) were assessed at months 0, 1, 2, and 4. Mixed models for repeated measures tested moderation with fixed effects of treatment, time, CM, and all interactions. Planned subgroup analyses evaluated treatment*time in episodic and CM. Of 60 participants (MBCT-M N = 31, WL/TAU N = 29), 52% had CM. CM moderated the effect of MBCT-M on Severe Migraine Disability Assessment Scale, F(3, 205) = 3.68, p = 0.013; MBCT-M vs WL/TAU reduced the proportion of people reporting severe disability to a greater extent among people with episodic migraine (-40.0% vs -14.3%) than CM (-16.4% vs +8.7%). Subgroup analysis revealed MBCT-M (vs WL/TAU) significantly reduced Headache Disability Inventory for episodic (p = 0.011) but not CM (p = 0.268). MBCT-M is a promising treatment for reducing headache-related disability, with greater benefits in episodic than CM. ClinicalTrials.gov Identifier: NCT02443519. This study provides Class III evidence that MBCT-M reduces headache disability to a greater extent in people with episodic than CM.
Comparable studies
Other randomized controlled trials on meditation, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Alterations in Brain and Immune Function Produced by Mindfulness Meditation Healthy employees in a work environment | 2003 | Randomized controlled trial | n = 41 |
| Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients | 2000 | Randomized controlled trial | n = 145 |
| Open hearts build lives: Positive emotions, induced through loving-kindness meditation, build consequential personal resources. Working adults | 2008 | Randomized controlled trial | n = 139 |
| Short-term meditation training improves attention and self-regulation Undergraduate Chinese students | 2007 | Randomized controlled trial | n = 40 |
| Mindfulness-Based Cognitive Therapy for Depression: Replication and Exploration of Differential Relapse Prevention Effects. Recovered recurrently depressed patients | 2004 | Randomized controlled trial | n = 73 |
Citations in the library
Cited by 2
- Efficacy of mindfulness added to treatment as usual in patients with chronic migraine and medication overuse headache: a phase-III single-blind randomized-controlled trial (the MIND-CM study). The Journal of Headache and Pain July 14, 2023
- Effectiveness of Mindfulness-Based Cognitive Therapy on Pain Catastrophizing and Job Satisfaction of Employees with Migraine Headaches Avicenna Journal of Neuro Psycho Physiology November 19, 2022
Cites 6
- Mindfulness-based cognitive therapy for depression August 21, 2006
- Mindfulness-based cognitive therapy for residual depressive symptoms and relapse prophylaxis Current Opinion in Psychiatry December 11, 2015
- A Pilot Randomized Controlled Trial Comparing Mindfulness Meditation, Cognitive Therapy, and Mindfulness-Based Cognitive Therapy for Chronic Low Back Pain Pain Medicine November 1, 2019
- Does Mindfulness-Based Cognitive Therapy for Migraine Reduce Migraine-Related Disability in People with Episodic and Chronic Migraine? A Phase 2b Pilot Randomized Clinical Trial Headache: The Journal of Head and Face Pain September 26, 2019
- The relationship between chronic musculoskeletal pain, anxiety and mindfulness: Adjustments to the Fear-Avoidance Model of Chronic Pain Scandinavian Journal of Pain October 1, 2017
and 1 more in the library